/Amgen%20office%20building%20is%20shown%20in%20Tampa%2C%20FL%2C%20USA%20By%20JHVEPhoto.jpeg)
Amgen has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.
/Pfizer%20Inc_%20NY%20HQ-by%20JHVEPhoto%20via%20iStock.jpg)
While Pfizer has trailed the broader market over the past year, Wall Street still sees room for upside and remains moderately optimistic about the company's prospects.
We look at five ETFs that can help investors leverage some of the trends expected to define the markets in the back half of the year.
/AMGEN%20Inc_%20HQ%20sign-%20by%20JHVEPhoto%20via%20iStock.jpg)
Amgen has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.
/Pfizer%20Inc_%20meds-by%20SteveAllenPhoto%20via%20iStock.jpg)
Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.
/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Gilead Sciences has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.
/Pfizer%20Inc_%20logo%20sign-by%20JHVEPhoto%20via%20iStock.jpg)
Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.
Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.
Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.
/Abbvie%20Inc%20HQ%20photo-by%20vzphotos%20via%20iStock.jpg)
Despite AbbVie’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.